Department of Immunology, Bernhard Nocht Institute for Tropical Medicine, Hamburg, Germany.
German Center for Infection Research (DZIF) Partner Site Hamburg/Lübeck/Borstel, Germany.
Antimicrob Agents Chemother. 2018 Mar 27;62(4). doi: 10.1128/AAC.01732-17. Print 2018 Apr.
Scrub typhus is a potentially lethal infection caused by the obligate intracellular bacterium Reports on the emergence of doxycycline-resistant strains highlight the urgent need to develop novel antiinfectives against scrub typhus. Corallopyronin A (CorA) is a novel α-pyrone compound synthesized by the myxobacterium that was characterized as a noncompetitive inhibitor of the switch region of the bacterial RNA polymerase (RNAP). We investigated the antimicrobial action of CorA against the human-pathogenic Karp strain of and The MIC of CorA against was remarkably low (0.0078 μg/ml), 16-fold lower than that against In the lethal intraperitoneal mouse infection model, a minimum daily dose of 100 μg CorA protected 100% of infected mice. Two days of treatment were sufficient to confer protection. In contrast to BALB/c mice, SCID mice succumbed to the infection despite treatment with CorA or tetracycline, suggesting that antimicrobial treatment required synergistic action of the adaptive immune response. Similar to tetracycline, CorA did not prevent latent infection of However, latency was not caused by acquisition of antimicrobial resistance, since reisolated from latently infected BALB/c mice remained fully susceptible to CorA. No mutations were found in the CorA-binding regions of the β and β' RNAP subunit genes and Inhibition of the RNAP switch region of by CorA is therefore a novel and highly potent target for antimicrobial therapy for scrub typhus.
恙虫病是一种潜在致命的感染,由专性细胞内细菌引起。有关强力霉素耐药株出现的报告强调了迫切需要开发针对恙虫病的新型抗感染药物。珊瑚酮 A(CorA)是一种由粘细菌合成的新型α-吡喃酮化合物,被鉴定为细菌 RNA 聚合酶(RNAP)开关区域的非竞争性抑制剂。我们研究了 CorA 对人类致病的恙虫病 Karp 株的抗菌作用。CorA 对 的 MIC 非常低(0.0078 μg/ml),比 低 16 倍。在致命的腹腔内感染小鼠模型中,每日最低剂量 100 μg CorA 可保护 100%感染的小鼠。两天的治疗即可提供保护。与 BALB/c 小鼠不同,SCID 小鼠尽管接受 CorA 或四环素治疗仍死于感染,这表明抗菌治疗需要适应性免疫反应的协同作用。与四环素相似,CorA 并未预防 的潜伏感染。然而,潜伏感染不是由于获得了抗微生物药物的耐药性引起的,因为从潜伏感染的 BALB/c 小鼠中重新分离的 仍然对 CorA 完全敏感。未在 CorA 结合的 β 和 β'RNAP 亚基基因 和 中发现突变。因此,CorA 抑制 的 RNAP 开关区域是一种针对恙虫病的新型、高效的抗菌治疗靶点。